Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
24 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pathios-therapeutics-appoints-jon-wigginton-md-as-non-executive-director-302564962.html
24 Mar 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/pathios-therapeutics-names-sumeet-ambarkhane-as-chief-medical-officer/
24 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pathios-therapeutics-appoints-sumeet-ambarkhane-md-as-chief-medical-officer-302408287.html
20 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pathios-therapeutics-announces-dosing-of-first-patient-in-phase-12-clinical-study-of-gpr65-inhibitor-ptt-4256-in-patients-with-advanced-solid-cancers-302310915.html
09 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pathios-therapeutics-appoints-paul-g-higham-as-chief-executive-officer-as-company-prepares-to-enter-the-clinic-302191187.html
18 Apr 2024
// Reynald Castañeda ENDPTS
https://endpts.com/pathios-rakes-in-25m-to-help-start-trials-for-gpr65-inhibitor/
Drugs in Development
Details:
PTT-4256 is an oral, highly potent, and selective small molecule inhibitor of the pH-sensing GPR65. It is being investigated for solid tumors.
Lead Product(s): PTT-4256
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2024
Lead Product(s) : PTT-4256
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pathios Begins Phase 1/2 Study of PTT-4256 GPR65 Inhibitor in Advanced Solid Cancers
Details : PTT-4256 is an oral, highly potent, and selective small molecule inhibitor of the pH-sensing GPR65. It is being investigated for solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2024
Details:
PTT-4256 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): PTT-4256
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2024
Lead Product(s) : PTT-4256
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Details : PTT-4256 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2024
Details:
The net Proceeds will be used to advance the clinical development of the leading candidate, PTT-4256, currently undergoing early-stage evaluation for neoplasm treatment.
Lead Product(s): PTT-4256
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 18, 2024
Lead Product(s) : PTT-4256
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $25.0 million
Deal Type : Series B Financing
Pathios Therapeutics Raises $25M in Series B Financing for First-in-Class Immunotherapy
Details : The net Proceeds will be used to advance the clinical development of the leading candidate, PTT-4256, currently undergoing early-stage evaluation for neoplasm treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 18, 2024
Details:
The grant funding will enable the company to expand its development of novel small molecule GPR65 inhibitors into the area of a possible treatment of malignant brain tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : UK Government
Deal Size : Undisclosed
Deal Type : Funding
Details : The grant funding will enable the company to expand its development of novel small molecule GPR65 inhibitors into the area of a possible treatment of malignant brain tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 27, 2023
Details:
Findings to showcase the promise of company's 'Macrophage Conditioning' approach in reversing immunosuppression within acidic tumor microenvironment and driving anti-tumor activity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings to showcase the promise of company's 'Macrophage Conditioning' approach in reversing immunosuppression within acidic tumor microenvironment and driving anti-tumor activity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 03, 2022
Details:
In the research presented, Pathios evaluated the impact of PTT-3196, an orally bioavailable, potent and selective GPR65 inhibitor, on expression of key immune-related genes and tumor growth in a highly glycolytic RCC PDX model implanted in NCG mice.
Lead Product(s): PTT-3196
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2021
Lead Product(s) : PTT-3196
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the research presented, Pathios evaluated the impact of PTT-3196, an orally bioavailable, potent and selective GPR65 inhibitor, on expression of key immune-related genes and tumor growth in a highly glycolytic RCC PDX model implanted in NCG mice.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2021
Details:
Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Innovate Biopharmaceuticals
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Innovate Biopharmaceuticals
Deal Size : $475.0 million
Deal Type : Funding
Pathios Therapeutics Receives £350K Funding Reward From Innovate UK
Details : Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
